Lilly's retatrutide outperforms Ozempic in head-to-head diabetes trial
Start here
Eli Lilly reported that its triple-G agonist retatrutide beat Novo Nordisk's Ozempic in a large head-to-head diabetes study. At 80 weeks, the highest-dose retatrutide group saw A1c fall 2.2 percentage points and weight fall 20.9%, compared with 1.8 percentage points and 9.4% for Ozempic. The reported results are based only on participants who stayed on treatment rather than all randomized participants, a caveat that will draw scrutiny as the data are reviewed. Further details, including full safety results and regulatory implications, are not yet available from the published coverage.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- statnews.comPickSTAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
Lilly says retatrutide beat Ozempic at lowering blood sugar and reducing weight in a large head-to-head diabetes study. After 80 weeks, the highest-dose retatrutide group saw A1c fall 2.2 percentage points and weight fall 20.9%, versus 1.8 percentage points and 9.4% for the Ozempic group. The results are based only on participants who stayed on treatment, not all participants.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 28 19:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.